HomeCompareIMPL vs EPRT

IMPL vs EPRT: Dividend Comparison 2026

IMPL yields 5000.00% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMPL wins by $62217131802825.29M in total portfolio value
10 years
IMPL
IMPL
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full IMPL calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — IMPL vs EPRT

📍 IMPL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMPLEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMPL + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMPL pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMPL
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, IMPL beats the other by $50,882,683,244,271,470,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMPL + EPRT for your $10,000?

IMPL: 50%EPRT: 50%
100% EPRT50/50100% IMPL
Portfolio after 10yr
$31108565901412.71M
Annual income
$29,930,990,143,689,114,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

IMPL
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
-23.9
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMPL buys
0
EPRT buys
0
No recent congressional trades found for IMPL or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMPLEPRT
Forward yield5000.00%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$62217131802825.35M$63.4K
Annual income after 10y$59,861,980,287,378,210,000.00$12,840.73
Total dividends collected$62057786341622.61M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: IMPL vs EPRT ($10,000, DRIP)

YearIMPL PortfolioIMPL Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$510,700$500,000.00$11,205$505.18+$499.5KIMPL
2$24,410,935$23,864,485.98$12,672$682.46+$24.40MIMPL
3$1,092,192,501$1,066,072,800.30$14,490$930.48+$1092.18MIMPL
4$45,746,366,951$44,577,720,975.17$16,786$1,282.69+$45746.35MIMPL
5$1,793,932,828,410$1,744,984,215,772.56$19,753$1,791.56+$1793932.81MIMPL
6$65,871,973,805,320$63,952,465,678,921.49$23,677$2,541.64+$65871973.78MIMPL
7$2,265,146,887,602,700$2,194,663,875,631,007.20$29,008$3,672.99+$2265146887.57MIMPL
8$72,954,689,148,998,180$70,530,981,979,263,280.00$36,463$5,425.08+$72954689148.96MIMPL
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$47,238$8,221.57+$2201076182660.84MIMPL
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$63,385$12,840.73+$62217131802825.29MIMPL

IMPL vs EPRT: Complete Analysis 2026

IMPLStock

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Full IMPL Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this IMPL vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMPL vs SCHDIMPL vs JEPIIMPL vs OIMPL vs KOIMPL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.